{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:41:10Z","timestamp":1773873670742,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jiac.2023.09.008","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T05:31:58Z","timestamp":1694237518000},"page":"147-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ensitrelvir eradicates persistent SARS-CoV-2 infection in a follicular lymphoma patient treated with anti-CD20 antibodies"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7160-5635","authenticated-orcid":false,"given":"Ippei","family":"Sakamaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiju","family":"Negoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2023.09.008_bib1","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma","volume":"5","author":"Perry","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jiac.2023.09.008_bib2","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jiac.2023.09.008_bib3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjh.18151","article-title":"Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in patients with haematological diseases treated with anti-CD20 antibodies: an observational study","volume":"197","author":"Nishikubo","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jiac.2023.09.008_bib4","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/bloodadvances.2021006302","article-title":"CD19-positive lymphocyte count is critical for acquisition of anti-SARSCoV-2 IgG after vaccination in B-cell lymphoma","volume":"6","author":"Okamoto","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jiac.2023.09.008_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-021-03247-y","article-title":"Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of antiCD20 antibody","volume":"115","author":"Funakoshi","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jiac.2023.09.008_bib6","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jiac.2023.09.008_bib7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ajh.26209","article-title":"Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy","volume":"96","author":"Dul\u00e9ry","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jiac.2023.09.008_bib8","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2023.09.008_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2023.09.008_bib10","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/ciac933","article-title":"Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study","volume":"76","author":"Mukae","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"628","key":"10.1016\/j.jiac.2023.09.008_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci Transl Med"},{"issue":"15","key":"10.1016\/j.jiac.2023.09.008_bib12","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2300212X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2300212X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:06:58Z","timestamp":1761160018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X2300212X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1341321X2300212X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2023.09.008","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ensitrelvir eradicates persistent SARS-CoV-2 infection in a follicular lymphoma patient treated with anti-CD20 antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2023.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}